Leflunomide — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

6 Recruiting

5 Completed trials

11 Sponsors

21 Countries

Phase III

Phase II

Phase IV

Phase III: 5 Phase II: 3 Phase III/IV: 1 Phase IV: 3

Indications tested

Rheumatoid arthritis 3 Dermatomyositis 2 Polymyositis 2 Sjogren's syndrome 2 Psoriatic arthropathy 1 Idiopathic inflammatory myopathy 1

Sponsors using this IMP

Pfizer Inc. 2 Argenx 1 Assistance Publique Hopitaux De Paris 1 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 1 Janssen - Cilag International 1 Karolinska Institutet 1 Les Hopitaux Universitaires De Strasbourg 1 Universitaetsklinikum Heidelberg AöR 1 Universitair Medisch Centrum Groningen 1 Universitair Medisch Centrum Utrecht 1 UZ Leuven 1

All trials

12 total

A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active convent… Pending

2024-516723-14-00 Phase IV 4 countries Karolinska Institutet
C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting

2022-502739-20-00 Phase III 10 countries Pfizer Inc.
An open-label extension study with dazukibart for participants with idiopathic inflammatory myopathies (including DM or PM) who have complet… Recruiting

2024-514648-10-00 Phase III 6 countries Pfizer Inc.
Treatment with leflunomide in patients with polymyalgia rheumatica Recruiting

2024-514210-12-00 Phase III 1 country Universitair Medisch Centrum Groningen
A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting

2022-502851-79-00 Phase III 19 countries Argenx
An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting

2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting

2024-516704-41-00 Phase III/IV 1 country Les Hopitaux Universitaires De Strasbourg
Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point… Ended

2024-511530-12-01 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients Ended

2023-510054-16-00 Phase II 7 countries Assistance Publique Hopitaux De Paris
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Cer… Ended

2023-504045-31-00 Phase II 3 countries Janssen - Cilag International
RepurpSS-II study Ended

2024-510904-36-00 Phase II 1 country Universitair Medisch Centrum Utrecht
RCT part: COBRA-Slim with or without fast access to TNF blockade for remission induction in early RA. LTE part: Long Term observational fol… Ended

2023-510189-28-00 Phase IV 1 country UZ Leuven

Showing 1–12 of 12 trials

← All drugs A–Z